{"prompt": "['Protocol VX18-445-109, Version 1.0', 'Page 54 of 60', 'Subject or investigator noncompliance', 'Unsatisfactory subject enrollment', 'Lack of adherence to protocol procedures', 'Lack of evaluable and/or complete data', 'Potentially unacceptable risk to study subjects', 'Decision to modify drug development plan', 'Decision by the FDA or other regulatory authority', 'Written notification that includes the reason for the clinical study termination is required.', '13.2.8', 'End of Study', 'The end of study is defined as the last scheduled visit (or scheduled contact) of the last subject.', '13.3', 'Data Quality Assurance', 'Vertex or its designated representative will conduct a study site visit to verify the qualifications', 'of each investigator, inspect clinical study site facilities, and inform the investigator of', 'responsibilities and procedures for ensuring adequate and correct study documentation. Vertex', 'will provide, or assess and approve, any electronic data capture (EDC) tools.', 'The investigator is required to prepare and maintain adequate and accurate case histories', 'designed to record all observations and other data pertinent to the study for each subject. Data', 'collected during the study, including results from screening, will be recorded in a data capture', \"system for each enrolled subject. Each subject's set of captured data records, once complete, will\", 'be signed and dated by the investigator.', '13.4', 'Monitoring', 'Monitoring and auditing procedures developed or approved by Vertex will be followed to', 'comply with GCP Guidelines. On-site checking of the data captured for the study/SAE Forms for', 'completeness and clarity, and clarification of administrative matters will be performed.', 'The study will be monitored by Vertex or its designee. Monitoring will be done by personal', 'visits from a representative of Vertex or designee (study site monitor), who will review the data', 'captured for the study/SAE Forms and source documents. The study site monitor will ensure that', 'the investigation is conducted according to the protocol design and regulatory requirements.', '13.5', 'Electronic Data Capture', 'Sites will use an EDC tool to record data for each enrolled subject.', \"It is the investigator's responsibility to ensure the accuracy, completeness, clarity, and timeliness\", 'of the data reported. The investigator is required to prepare and maintain adequate and accurate', 'case histories designed to record all observations and other data pertinent to the study for each', 'subject, including the dates and details of study procedures, AEs, other observations, and subject', 'status.', \"The audit trail entry will show the user's identification information and the date and time of any\", 'correction. The investigator will provide formal approval of all data reported to Vertex, including', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 55 of 60', 'any changes made, to endorse the final submitted data for the subjects for whom the investigator', 'is responsible.', '13.6', 'Confidentiality and Disclosure', 'Any and all scientific, commercial, and technical information disclosed by Vertex in this', 'protocol or elsewhere will be considered the confidential and proprietary property of Vertex. The', 'investigator shall hold such information in confidence and shall not disclose the information to', \"any third party except to such of the investigator's employees and staff as have been made aware\", 'that the information is confidential and who are bound to treat it as such and to whom disclosure', 'is necessary to evaluate that information. The investigator shall not use such information for any', 'purpose other than determining mutual interest in performing the study and, if the parties decide', 'to proceed with the study, for the purpose of conducting the study.', 'The investigator understands that the information developed from this clinical study will be used', 'by Vertex in connection with the development of the study drug and other drugs and diagnostics,', 'and therefore may be disclosed as required to other clinical investigators, business partners and', 'associates, the FDA, and other government agencies. The investigator also understands that, to', 'allow for the use of the information derived from the clinical study, the investigator has the', 'obligation to provide Vertex with complete test results and all data developed in the study.', '13.7', 'Publications and Clinical Study Report', '13.7.1', 'Publication of Study Results', 'Vertex is committed to reporting the design and results of all clinical studies in a complete,', 'accurate, balanced, transparent, and timely manner, consistent with Good Publication Practices', '(GPP3). 21', 'Publication Planning: Vertex staff along with the lead principal investigators, the steering', 'committee, and/or the publication committee will work together to develop a publication plan.', 'Authorship: Authorship of publications will be determined based on the Recommendations for', 'Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, which', 'states that authorship should be based on the following 4 criteria2:', '1. Substantial contributions to conception and design, acquisition of data, or analysis and', 'interpretation of data;', '2. Drafting of the article or revising it critically for important intellectual content;', '3. Final approval of the version to be published; and', '4. Agreement to be accountable for all aspects of the work in ensuring that questions related', 'to the accuracy or integrity of any part of the work are appropriately investigated and', 'resolved.', 'All authors must meet conditions 1, 2, 3, and 4. All persons designated as authors should qualify', 'for authorship, and all those who qualify should be listed. Contributions such as medical writing,', 'enrollment of subjects, acquisition of funding, collection of data, or general supervision of the', 'research group, alone, do not justify authorship.', 'Contributors: Contributors who meet fewer than all 4 of International Committee of Medical', 'Journal Editors (ICMJE) criteria for authorship will not be listed as authors, but their', 'Vertex Pharmaceuticals Incorporated']\n\n###\n\n", "completion": "END"}